Rempex Pharmaceuticals are developing Carbavance which contains the beta lactamase inhibitor RPX7009 combined with the beta-lactam antibiotic carbapenem as part of a treatment for hospitalized patients with serious bacterial infections. RPX7009 stops one of the primary defense mechanisms of the carbapenem-resistant Enterobacteriaceae which is reported by the CDC to be a urgent threat. By some estimates, carbapenem-resistant Enterobacteriaceae kill up to 50% of infected patients.
Beryllium scientists helped determined the structure of the different complexes and this work contributed to the understanding of the binding and function of RPX7009. The work was recently published in the Journal of Medicinal Chemistry.